The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cytunepharma.com

Founded Year

2007

Stage

Acquired | Acquired

Total Raised

$7.98M

About Cytune Pharma

Cytune Pharma is developing a portfolio of immunotherapeutic agents to treat primarily cancer. Cytune's compound, CYP 0150, is a human interleukin-15 linked to its effector.

Cytune Pharma Headquarter Location

7 Rue Amedee Menard

Nantes, 44300,

France

+33 (0) 666 495 594

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cytune Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cytune Pharma is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cytune Pharma Patents

Cytune Pharma has filed 9 patents.

The 3 most popular patent topics include:

  • Interleukins
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/8/2014

3/15/2022

Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Interleukins

Grant

Application Date

8/8/2014

Grant Date

3/15/2022

Title

Related Topics

Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Interleukins

Status

Grant

Latest Cytune Pharma News

Demand for Fusion Protein Biosimilars is increasing for the Treatment of Cancer Market 2032 : Fact MR

Mar 9, 2022

Search jobs 09-Mar-2022 Demand for Fusion Protein Biosimilars is increasing for the Treatment of Cancer Market 2032 : Fact MR Biologic drugs are commonly used to treat various diseases but their high cost has raised the emerging scope for biosimilars in the market. A fusion protein biosimilars has come forth as a new modality, as an alternate of biologic products. The fusion protein biosimilars combines the customized pharmacological properties of biological ligands, together with multiple functions of the fragmented crystallizable domain of immunoglobulins. The fusion protein biosimilars are used in several clinical studies based on applications like cancer, HIV-AIDS, chronic inflammatory diseases, and many other chronic diseases. Request a report sample to gain comprehensive insights at   https://www.factmr.com/connectus/sample?flag=S&rep_id=5690 After proven effective against chronic diseases such as cancer, chronic inflammatory diseases, and cardiovascular, the demand for fusion protein biosimilar is expected to surge in the forecasting period. More than 11 fusion protein drugs have been approved by the Food and Drug Administration (FDA) and several new Fc fusion proteins are in the developing stage. This increasing approval of novel new biosimilar drugs has presented a lucrative growth opportunity for the fusion proteins drugs market. “To strengthen their footprint in the global market, key manufactures have increased their focus on the developing of more effective biosimilars drugs. Besides this, new product launches and collaboration with other companies will assist them to expand their regional presence and existing product portfolio,” says the Fact.MR analyst. Key Takeaways In Europe, the U.K. dominates the fusion protein biosimilars market owing to the presence of a well-defined regulatory framework. Increasing approval of new biosimilar drugs is driving the growth in the U.S. Due to the increasing industrial biologic development and ongoing improvement in the regulatory environment, the demand for fusion protein biosimilar is expected to surge in developed economies. Owing to the increasing prevalence of chronic diseases and the rapidly expanding healthcare infrastructure, Asia Pacific has emerged as the fastest-growing fusion protein biosimilars market Key Drivers Favorable regulatory scenarios and expansion of the healthcare infrastructure are driving the biosimilars market. Growing number of approvals and product launches will fuel the growth of the market. Key Restraints Strict regulatory approvals is the factor restraining the growth of the fusion protein biosimilars market. Competitive Landscape Prominent players in the market include Pfizer Inc., Eli Lilly and Company, Sandoz International GmbH, F. Hoffmann-La Roche Ltd., AbbVie Inc., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis, Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Fresenius Kabi AG, STADA Arzneimittel AG, Celltrion Healthcare Co.Ltd., Thermo Fisher Scientific Inc., Daiichi Sankyo Co Ltd., Aurobindo Pharma, Absolute Antibody, and Bioverativ Therapeutics Inc. Key players are acquiring and collaborating with other companies to gain maximum revenue share and expand their regional presence. For instance, SOTIO had acquired Cytune Pharma to allow the company the usage of Cytune’s SO-C101 in 2018. In January 2020, Coherus BioSciences, Inc. entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd More Insights on the Fusion Protein Biosimilars Market Fact.MR has published unbiased analysis of the fusion protein biosimilars market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (cytokines recombinant protein, immunoglobin (Ig) fusion protein, parathyroid hormone (PTPH) fusion protein), application (cancer, HIV-AIDS, respiratory disease, cardiovascular disorder, and ophthalmology) end user (hospitals and Research institutes), across seven regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa). Read More Trending Reports of Fact.MR- Why choose Fact.MR? Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability. Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain: Fluoro Enzymatic Assays Market –  https://www.factmr.com/report/fluoro-enzymatic-assays-market Shower Chairs Market –  https://www.factmr.com/report/shower-chairs-market About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact:

  • When was Cytune Pharma founded?

    Cytune Pharma was founded in 2007.

  • Where is Cytune Pharma's headquarters?

    Cytune Pharma's headquarters is located at 7 Rue Amedee Menard, Nantes.

  • What is Cytune Pharma's latest funding round?

    Cytune Pharma's latest funding round is Acquired.

  • How much did Cytune Pharma raise?

    Cytune Pharma raised a total of $7.98M.

  • Who are the investors of Cytune Pharma?

    Investors of Cytune Pharma include PPF Group, SOTIO, IDEE, Sodera, Remora Capital and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.